Sandoz Group AG (SWX:SDZ)
54.96
+0.22 (0.40%)
Nov 24, 2025, 11:03 AM CET
Sandoz Group AG Revenue
Sandoz Group AG had revenue of $5.27B USD in the half year ending June 30, 2025, with 6.80% growth. This brings the company's revenue in the last twelve months to $10.59B, up 4.71% year-over-year. In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth.
Revenue (ttm)
$10.59B
Revenue Growth
+4.71%
P/S Ratio
2.80
Revenue / Employee
$480.16K
Employees
22,049
Market Cap
23.58B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
| Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
| Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
| Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
| Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.49B |
| Novartis AG | 44.95B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
| Straumann Holding AG | 2.58B |
Sandoz Group AG News
- 7 days ago - Sandoz Announces Launch Of TYRUKO In The US - Nasdaq
- 19 days ago - Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal - Nasdaq
- 19 days ago - Evotec (EVO) Sells Biologics Site to Sandoz for $350M - GuruFocus
- 19 days ago - Evotec signs deal with Sandoz for Just - Evotec Biologics site - Seeking Alpha
- 23 days ago - SDZNY vs. STVN: Which Stock Is the Better Value Option? - Nasdaq
- 24 days ago - Sandoz Group AG (SDZNY) Q3 2025 Sales Call Transcript - Seeking Alpha
- 25 days ago - Sandoz Group AG (SDZNY) Q3 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 6 weeks ago - FDA Gives Tentative Nod to Sandoz's Generic Version of Pfizer's Inlyta - GuruFocus